Disease on EC 1.1.1.42 - isocitrate dehydrogenase (NADP+)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.
Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma.
Adenoma
Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa.
Arteriovenous Malformations
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma.
Astrocytoma
A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Diagnostic and prognostic markers in gliomas.
Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.
Genetic alterations and signaling pathways in the evolution of gliomas.
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
IDH1 R132H mutation in a pilocytic astrocytoma: a case report.
IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Metabolic modulation of epigenetics in gliomas.
Molecular pathogenesis of IDH mutations in gliomas.
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI.
Pathological classification of brain tumors.
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
PCR- and Restriction Endonuclease-Based Detection of IDH1 Mutations.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Brain Neoplasms
5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.
An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells.
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.
Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation.
Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel.
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.
Tissue mechanics promote IDH1-dependent HIF1?-tenascin C feedback to regulate glioblastoma aggression.
Breast Neoplasms
Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.
Relationship of glycolytic enzyme activities and response of breast cancer patients to chemotherapy: A preliminary report.
Carcinogenesis
Altered Expression of Oxidative Metabolism Related Genes in Cholangiocarcinomas.
Discovery of ?-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Isocitrate dehydrogenase 1 is downregulated during early skin tumorigenesis which can be inhibited by overexpression of manganese superoxide dismutase.
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
The emerging role of fumarate as an oncometabolite.
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Carcinoma
Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas.
Proteome of Metastatic Canine Mammary Carcinomas: Similarities to and Differences from Human Breast Cancer (†).
Relationship of glycolytic enzyme activities and response of breast cancer patients to chemotherapy: A preliminary report.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Carcinoma, Ehrlich Tumor
Changes in enzyme pattern of Ehrlich ascites tumor cells following serial cultivation in media with increased (hypertonic) NaCl content.
Carcinoma, Hepatocellular
Calcium sensitive isocitrate and 2-oxoglutarate dehydrogenase activities in rat liver and AS-30D hepatoma mitochondria.
Carcinoma, Non-Small-Cell Lung
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Carcinoma, Squamous Cell
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Cardiotoxicity
A possible mechanism of adriamycin cardiotoxicity. Inhibition of NADP-linked isocitrate dehydrogenase.
Chemical and Drug Induced Liver Injury
[The intensity of free radical oxidation and catalytic properties of the rat liver NADP-isocitrate dehydrogenase in the norm and in toxic hepatitis]
[Thioctic acid action on glutathione-dependent antioxidant system functioning at toxic hepatitis of rats]
Cholangiocarcinoma
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Chondroma
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis.
Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas.
Chondrosarcoma
An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing.
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis.
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Induction of sarcomas by mutant IDH2.
Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
Metabolic consequences of oncogenic IDH mutations.
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Colorectal Neoplasms
Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Dehydration
Activity of isocitrate dehydrogenase from three filamentous fungi in relation to osmotic and solute effects.
Sucrose phosphate synthase activity and the co-ordination of carbon partitioning during sucrose and amino acid accumulation in desiccation-tolerant leaf material of the C4 resurrection plant Sporobolus stapfianus during dehydration.
Dermatitis, Phototoxic
Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase.
Enchondromatosis
Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1DH1) mutation in a patient with Ollier disease: evidence for a causal relationship.
The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.
Ependymoma
Lack of IDH1 mutation in astroblastomas suggests putative origin from ependymoglial cells?
Fibroma
Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1DH1) mutation in a patient with Ollier disease: evidence for a causal relationship.
Ganglioglioma
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas.
Ganglioneuroma
A case of oligodendroglioma with prominent neuronal differentiation.
Glioblastoma
Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastoma.
An IDH1-mutated primary gliosarcoma: case report.
Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.
Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients.
Biochemical, Cellular and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny.
Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Defective p53 antiangiogenic signaling in glioblastoma.
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas.
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Genetic alterations and signaling pathways in the evolution of gliomas.
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation.
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas.
Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
Gliosis versus glioma?: don't grade until you know.
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.
Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas.
IDH mutations in glioma and acute myeloid leukemia.
IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.
IDH1 and IDH2 mutations in gliomas.
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.
IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
IDH1 mutation of gliomas with long-term survival analysis.
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
IDH1R¹³²H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Intramedullary spinal glioblastoma metastasis from anaplastic astrocytoma of cerebellum: A case report and review of the literature.
Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.
Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Isocitrate dehydrogenase mutations in gliomas.
Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Metabolic modulation of epigenetics in gliomas.
Molecular pathogenesis of IDH mutations in gliomas.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
NADP(+)-dependent IDH1(R132) mutation and its relevance for glioma patient survival.
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Non-invasive in vivo assessment of IDH1 mutational status in glioma.
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.
Prognostic Value of MGMT Promoter Methylation and TP53 Mutation in Glioblastomas Depends on IDH1 Mutation.
Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Structural, Kinetic and Chemical Mechanism of Isocitrate Dehydrogenase-1 from Mycobacterium tuberculosis.
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view.
Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme.
[Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
Glioma
1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.
A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation.
An IDH1-mutated primary gliosarcoma: case report.
An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas.
An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells.
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.
Analysis of Isocitrate Dehydrogenase 1 Mutation in 97 Patients with Glioma.
Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.
Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.
Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny.
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
COLD PCR HRM: A highly sensitive detection method for IDH1 mutations.
Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies.
Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations.
Diagnostic and prognostic markers in gliomas.
Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Enzymes related to energy metabolism in human gliomas.
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation.
Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression.
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.
Gene markers in brain tumors: what the epileptologist should know.
Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype.
Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1? and ?-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance.
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Identification of a new selective chemical inhibitor of mutant isocitrate dehydrogenase-1.
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas.
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
IDH mutations in cancer and progress toward development of targeted therapeutics.
IDH mutations in human glioma.
IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas.
IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil.
IDH1 and IDH2 mutations in gliomas.
IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
IDH1 mutation-associated long non-coding RNA expression profile changes in glioma.
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.
IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
IDH1, lipid metabolism and cancer: Shedding new light on old ideas.
IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.
IDH1/2 mutation detection in gliomas.
IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis.
IDH1R¹³²H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
Imaging Markers of Isocitrate Dehydrogenase-1 Mutations in Gliomas.
Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas.
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1.
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Isocitrate dehydrogenase 1 and 2 mutations in gliomas.
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Isocitrate dehydrogenase mutations in gliomas.
KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status.
Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
Massive dissemination of adult glioblastomas.
Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas.
Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells.
Metabolic consequences of oncogenic IDH mutations.
Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1.
Metabolic syndromes and malignant transformation: where the twain shall meet.
Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation.
Molecular classification of gliomas.
Molecular markers in low-grade gliomas: predictive or prognostic?
Molecular pathogenesis of IDH mutations in gliomas.
Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.
Moving toward molecular classification of diffuse gliomas in adults.
MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance.
Mutant IDH1: An immunotherapeutic target in tumors.
Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor??B activation in a hypoxia?inducible factor 1?? dependent manner.
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
NADP(+)-dependent IDH1(R132) mutation and its relevance for glioma patient survival.
New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Non-invasive in vivo assessment of IDH1 mutational status in glioma.
Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches.
Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies.
Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Papillary tumor of the pineal region: a case involving isocitrate dehydrogenase (IDH) genotyping.
Pathological classification of brain tumors.
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.
Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm.
Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Prognostic stratification of gliomatosis cerebri by IDH1(R132H) and INA expression.
Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.
R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/?-catenin signaling.
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1? upregulation in adult glioma.
Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing.
Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma.
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry.
Relationship between IDH1 mutation and preoperative seizure in low-grade gliomas: A meta-analysis.
Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases.
Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Seizures and gliomas - towards a single therapeutic approach.
Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Textiloma resembling anaplastic progression of an isocitrate dehydrogenase 1 (IDH1) mutant, low grade glioma.
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
The CpG Island Methylator Phenotype: What's in a Name?
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.
Tissue mechanics promote IDH1-dependent HIF1?-tenascin C feedback to regulate glioblastoma aggression.
Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.
Usefulness of immunohistochemical expression analysis of metabolic-related molecules to differentiate between intracranial neoplastic and non-neoplastic lesions.
[Expression of isocitrate dehydrogenase 1 gene R132H and its diagnostic application in glioma].
[Relationship between IDH1 mutation and clinic pathologic features in human supratentorial WHO grade II gliomas].
Gliosarcoma
An IDH1-mutated primary gliosarcoma: case report.
Hematologic Neoplasms
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice.
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Hyperaldosteronism
Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa.
Hyperglycemia
Upregulation of cytosolic NADP(+)-dependent isocitrate dehydrogenase by hyperglycemia protects renal cells against oxidative stress.
Upregulation of cytosolic NADP+-dependent isocitrate dehydrogenase by hyperglycemia protects renal cells against oxidative stress.
Hypokinesia
[Oxidative enzyme activity of the tricarboxylic acid cycle in rat skeletal muscles in hypokinesia]
Hypothyroidism
Changes of activity and kinetics of certain liver and heart enzymes of hypothyroid and T(3)-treated rats.
Infertility, Male
Identification of miRNAs and their targets by high-throughput sequencing and degradome analysis in cytoplasmic male-sterile line NJCMS1A and its maintainer NJCMS1B of soybean.
Molecular cloning, sequence characterization of a novel pepper gene NADP-ICDH and its effect on cytoplasmic male sterility.
Intellectual Disability
Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma.
Leukemia
Enzyme activities of NADPH-forming metabolic pathways in normal and leukemic leukocytes.
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Leukemia, Myeloid, Acute
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
Enzyme activities of NADPH-forming metabolic pathways in normal and leukemic leukocytes.
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish.
IDH mutations in cancer and progress toward development of targeted therapeutics.
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
IDH1 and IDH2 mutations in pediatric acute leukemia.
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.
IDH1, lipid metabolism and cancer: Shedding new light on old ideas.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1.
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Metabolic consequences of oncogenic IDH mutations.
Metabolic syndromes and malignant transformation: where the twain shall meet.
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Oncometabolite d-2-hydroxyglutarate impairs ?-ketoglutarate dehydrogenase and contractile function in rodent heart.
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance.
Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
The oncometabolite R-2-hydroxyglutarate activates NF-?B-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
[Clinical significance of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
[Detection of isocitrate dehydrogenase 1 gene mutation in 205 AML patients and its clinical significance].
Liver Neoplasms
Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer.
Lung Neoplasms
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Lymphoma
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Lymphoma, T-Cell
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Malaria
NADP-specific isocitrate dehydrogenase from the simian malaria parasite Plasmodium knowlesi: partial purification and characterization.
Melanoma
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Metabolic Diseases
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Myelodysplastic Syndromes
Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
IDH mutations in cancer and progress toward development of targeted therapeutics.
[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
Myocardial Infarction
[The dose-dependent influence of 3,5-dicarbometoxyphenylbiguanide on activity of the glutathione antioxidant system in heart and blood serum of rats with the experimental myocardial infarction].
Neoplasm Metastasis
Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases.
Neoplasms
A case of multicentric gliomas in both supra- and infratentorial regions with different histology: a case report.
A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
Action at a distance: allostery and the development of drugs to target cancer cell metabolism.
Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Anaplastic astrocytomas with abundant Rosenthal fibers in elderly patients: A diagnostic pitfall of high-grade gliomas.
Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.
Biliary cancer: Utility of next-generation sequencing for clinical management.
Biochemical, Cellular and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1.
Cancer metabolism: Key players in metabolic reprogramming.
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Changes in enzyme pattern of Ehrlich ascites tumor cells following serial cultivation in media with increased (hypertonic) NaCl content.
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis.
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Congenital glioneuronal tumor with neuropil-like islands.
Congenital oligodendroglioma: clinicopathologic and molecular assessment with review of the literature.
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Discovery of ?-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Docosahexaenoic Acid Modulates the Enterocyte Caco-2 Cell Expression of MicroRNAs Involved in Lipid Metabolism.
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Extracranial growth of glioblastoma multiforme.
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.
Genetic alterations and signaling pathways in the evolution of gliomas.
Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas.
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
Hypoxia Induces Production of L-2-Hydroxyglutarate.
Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.
IDH mutations in cancer and progress toward development of targeted therapeutics.
IDH mutations in liver cell plasticity and biliary cancer.
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
IDH1 and IDH2 mutations in gliomas.
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
IDH1 mutation of gliomas with long-term survival analysis.
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.
IDH1 Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA-Mediated Clamping PCR.
IDH1, lipid metabolism and cancer: Shedding new light on old ideas.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas.
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9.
Lactate dehydrogenase A silencing in IDH mutant gliomas.
Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status.
Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report.
Maffucci syndrome and neoplasms: a case report and review of the literature.
Malignant glioma: lessons from genomics, mouse models, and stem cells.
Metabolic consequences of oncogenic IDH mutations.
Molecular classification of gliomas.
Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network.
MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Mutant IDH1: An immunotherapeutic target in tumors.
Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies.
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Pathologic diversity of glioneuronal tumor with neuropil-like islands: A histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Pathological classification of brain tumors.
PDGFRA Amplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma.
Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Promoter methylation of WNT inhibitory factor-1 and expression pattern of WNT/?-catenin pathway in human astrocytoma: pathologic and prognostic correlations.
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics.
Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.
Sarcoma-like tumor originating from oligodendroglioma.
Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.
Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases.
Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-alpha and anticancer drugs.
Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1.
Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1.
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells.
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.
Tumor location and IDH1 mutation may predict intraoperative seizures during awake craniotomy.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme.
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Withaferin A suppresses tumor promoter 12-O-tetradecanoylphorbol 13-acetate-induced decreases in isocitrate dehydrogenase 1 activity and mitochondrial function in skin epidermal JB6 cells.
[Classification of gliomas. Current progress and perspectives].
[Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
[Expression and catalytic properties NADP-isocitrate dehydrogenase from the rat liver under normal conditions and following administration of tumor necrosis factor-alpha or thioctic acid].
[Feature analysis of IDH1 mutation in oligodendroglial tumors].
[Isozymes of NADP-dependent isocitrate dehydrogenase in normal and tumor tissues of various mouse strains and their hybrids]
Neoplasms, Neuroepithelial
Diffuse leptomeningeal neuroepithelial tumor: 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry.
Neuroblastoma
Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia.
Neurocytoma
A case of oligodendroglioma with prominent neuronal differentiation.
Neuroectodermal Tumors, Primitive
Massive dissemination of adult glioblastomas.
Oligodendroglioma
A case of oligodendroglioma with prominent neuronal differentiation.
Anaplastic Oligodendroglioma: Advances and Treatment Options.
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma.
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Diffuse leptomeningeal neuroepithelial tumor: 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry.
Findings from positron emission tomography and genetic analyses for cerebellar liponeurocytoma.
Genetic alterations and signaling pathways in the evolution of gliomas.
Gliosis versus glioma?: don't grade until you know.
IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Metabolic modulation of epigenetics in gliomas.
Molecular pathogenesis of IDH mutations in gliomas.
Molecular profile of oligodendrogliomas in young patients.
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
PCR- and Restriction Endonuclease-Based Detection of IDH1 Mutations.
Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Osteosarcoma
The expression and significance of IDH1 and p53 in osteosarcoma.
Up-regulated isocitrate dehydrogenase 1 suppresses proliferation, migration and invasion in osteosarcoma: In vitro and in vivo.
Polycythemia Vera
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
IDH1 and IDH2 mutations in pediatric acute leukemia.
Primary Myelofibrosis
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Reperfusion Injury
Role of cytosolic NADP+-dependent isocitrate dehydrogenase in ischemia-reperfusion injury in mouse kidney.
Retinitis Pigmentosa
Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle.
Retinoblastoma
An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells.
Sarcoma
Molecular classification of gliomas.
Sheep gene mapping: additional DNA markers included (CASB, CASK, LALBA, IGF-1 and AMH).
[Classification of gliomas. Current progress and perspectives].
Seizures
Relationship between IDH1 mutation and preoperative seizure in low-grade gliomas: A meta-analysis.
Tumor location and IDH1 mutation may predict intraoperative seizures during awake craniotomy.
Starvation
Cloning and expression analysis of the cytosolic NADP(+)-dependent isocitrate dehydrogenase from potato. Implications for nitrogen metabolism.
Purification, properties and enhanced expression under nitrogen starvation of the NADP+-isocitrate dehydrogenase from the cyanobacterium Phormidium laminosum.
The NADP+-isocitrate dehydrogenase gene (icd) is nitrogen regulated in cyanobacteria.
Thrombocythemia, Essential
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Thyroid Neoplasms
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Tuberculosis
Determination of Phosphorylation Sites for NADP-specific Isocitrate Dehydrogenase from Mycobacterium tuberculosis.
Structural, Kinetic and Chemical Mechanism of Isocitrate Dehydrogenase-1 from Mycobacterium tuberculosis.
Vitamin E Deficiency
Cellular membranes and membrane-bound enzymes in vitamin E deficiency. A histochemical, cytochemical, biochemical, and morphologic study of the liver of the Pekin duckling.